TFG Asset Management GP Ltd Buys New Stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

TFG Asset Management GP Ltd acquired a new stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 192,000 shares of the biopharmaceutical company's stock, valued at approximately $4,852,000. Celldex Therapeutics comprises approximately 1.2% of TFG Asset Management GP Ltd's holdings, making the stock its 14th biggest holding. TFG Asset Management GP Ltd owned about 0.29% of Celldex Therapeutics as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the company. Values First Advisors Inc. increased its holdings in shares of Celldex Therapeutics by 20.0% during the 4th quarter. Values First Advisors Inc. now owns 29,009 shares of the biopharmaceutical company's stock valued at $733,000 after purchasing an additional 4,837 shares in the last quarter. Barclays PLC grew its holdings in Celldex Therapeutics by 140.7% in the third quarter. Barclays PLC now owns 130,381 shares of the biopharmaceutical company's stock valued at $4,431,000 after purchasing an additional 76,207 shares during the period. SG Americas Securities LLC increased its position in shares of Celldex Therapeutics by 24.4% in the fourth quarter. SG Americas Securities LLC now owns 25,283 shares of the biopharmaceutical company's stock valued at $639,000 after buying an additional 4,967 shares in the last quarter. Invesco Ltd. lifted its position in shares of Celldex Therapeutics by 2.1% during the 4th quarter. Invesco Ltd. now owns 42,101 shares of the biopharmaceutical company's stock valued at $1,064,000 after buying an additional 871 shares in the last quarter. Finally, Sovran Advisors LLC acquired a new stake in Celldex Therapeutics in the 4th quarter valued at $2,867,000.

Analysts Set New Price Targets

CLDX has been the topic of a number of research reports. The Goldman Sachs Group decreased their price target on shares of Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating on the stock in a research note on Friday, May 9th. Morgan Stanley reduced their target price on shares of Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating for the company in a research report on Friday, May 9th. HC Wainwright restated a "buy" rating and set a $80.00 price target on shares of Celldex Therapeutics in a research report on Tuesday, May 6th. UBS Group cut their price objective on shares of Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a report on Friday, May 9th. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $67.00 price target on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $53.90.

Celldex Therapeutics Stock Down 0.6%

NASDAQ:CLDX traded down $0.12 on Friday, reaching $20.26. The company's stock had a trading volume of 111,076 shares, compared to its average volume of 892,672. Celldex Therapeutics, Inc. has a 12-month low of $14.40 and a 12-month high of $47.00. The stock has a 50 day moving average price of $18.90 and a 200 day moving average price of $22.45. The firm has a market cap of $1.34 billion, a price-to-earnings ratio of -7.88 and a beta of 1.39.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. The company had revenue of $0.70 million during the quarter, compared to analysts' expectations of $1.08 million. Equities research analysts expect that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.